U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07007793) titled 'A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism' on May 16.
Brief Summary: This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and unsuppression of Plasma Renin Activity (PRA) in approximately 180 participants >= 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics.
Baxdrostat (or placebo) will be admini...